Venclexta Kit
Product Images NDC 0074-0579

10 FDA label images from Abbvie Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Venclexta (NDC 0074-0579). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Following Chemical Structure For Venetoclax Is A Bcl-2 Inhibitor. It Is A Light Yellow To Dark Yellow Solid With The Empirical Formula C45h50cln7o7s And A Molecular Weight Of 868.44. Venetoclax Is Described Chemically As 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide). (Venetoclax Spl 01)

The Following Chemical Structure For Venetoclax Is A Bcl-2 Inhibitor. It Is A Light Yellow To Dark Yellow Solid With The Empirical Formula C45h50cln7o7s And A Molecular Weight Of 868.44. Venetoclax Is Described Chemically As 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide). (Venetoclax Spl 01)
Chemical structure of venetoclax, the active ingredient in Venclexta tablets. The diagram shows the molecule's detailed atomic connectivity and bonding arrangement in a 2D format.*
FDA Label Image

Figure 1. Kaplan-meier Curve Of Irc-assessed Progression-free Survival In Amplify (Venetoclax Spl 02)

Figure 1. Kaplan-meier Curve Of Irc-assessed Progression-free Survival In Amplify (Venetoclax Spl 02)
A Kaplan-Meier survival curve chart comparing progression-free survival between two patient groups: one treated with GClb (N=216) and one with VEN-G (N=216). The x-axis shows time in months up to 36 months, and the y-axis shows percentage progression-free survival from 0% to 100%. A table below the chart lists the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 1 (Venetoclax Spl 03)

Figure 1 (Venetoclax Spl 03)
A Kaplan-Meier survival curve comparing progression-free survival over time (months) between two groups: one treated with B + R and the other with VEN + R, with patient numbers at risk shown below the x-axis. The graph includes censored data points for each group.*
FDA Label Image

Figure 2 (Venetoclax Spl 04)

Figure 2 (Venetoclax Spl 04)
A survival curve chart depicting overall survival over time in months, comparing two groups labeled B+R (N=195) and VEN+R (N=194). The chart includes a line graph showing survival percentages on the vertical axis and months on the horizontal axis, with a table below indicating the number of patients at risk at various time points. Censored data points are marked with crosses on the lines.*
FDA Label Image

Figure 3 (Venetoclax Spl 05)

Figure 3 (Venetoclax Spl 05)
A Kaplan-Meier survival curve showing the probability of no event over time in months for two treatment groups, PBO+AZA and VEN+AZA. The graph includes a table beneath the plot indicating the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 4 (Venetoclax Spl 06)

Figure 4 (Venetoclax Spl 06)
Venclexta (venetoclax tablets) packaging label for a CLL/SLL Starting Pack containing 10 mg, 50 mg, and 100 mg film-coated oral tablets. The label shows the AbbVie Inc. logo, NDC 0078-0577-38, and storage information. It includes instructions to read the insert and safety warnings, highlighting the presence of venetoclax as the active ingredient.*
FDA Label Image

Ndc 0074-0579-28 Cll/sll Starting Pack Venclexta® (venetoclax Tablets) 10 mg, 50 mg, And 100 mg Starting Pack ! Warningcontact Your Doctor When You Receive This Medication.it May Be Necessary To Take Your First Dose In The Presence Of Your Doctor To Prevent A Potential Serious Side Effect. Dispenser: Each Time Venclexta Is Dispensed Give The Patient The Enclosed Medication Guide. Abbvie Rx Only Genentech (Venetoclax Spl 07)

Ndc 0074-0579-28 Cll/sll Starting Pack Venclexta® (venetoclax Tablets) 10 mg, 50 mg, And 100 mg Starting Pack ! Warningcontact Your Doctor When You Receive This Medication.it May Be Necessary To Take Your First Dose In The Presence Of Your Doctor To Prevent A Potential Serious Side Effect. Dispenser: Each Time Venclexta Is Dispensed Give The Patient The Enclosed Medication Guide. Abbvie Rx Only Genentech (Venetoclax Spl 07)
Venclexta 10 mg per tablet film-coated oral tablet carton containing 14 tablets. The packaging displays the AbbVie and Genentech logos and includes instructions to dispense the accompanying Medication Guide to each patient. It provides storage instructions and manufacturer information for AbbVie Inc. and Genentech USA, Inc.*
FDA Label Image

Ndc 0074-0561-14 Rx Only Venclexta® (venetoclax Tablets) 10 mg Per Tablet14 Tablets Dispense The Accompanying Medication Guide To Each Patient. Abbvie Genentech (Venetoclax Spl 08)

Ndc 0074-0561-14 Rx Only Venclexta® (venetoclax Tablets) 10 mg Per Tablet14 Tablets Dispense The Accompanying Medication Guide To Each Patient. Abbvie Genentech (Venetoclax Spl 08)
Packaging label for Venclexta 50 mg film-coated oral tablets by AbbVie Inc. The carton contains one daily blister with one 50 mg venetoclax tablet. The label displays the product name, strength, dosage form, NDC 0074-0566-11, and manufacturer information including AbbVie and Genentech. The design includes a pink band and tablet image.*
FDA Label Image

Ndc 0074-0566-11 Rx Only Venclexta® (venetoclax Tablets) 50 mg Per Tablet1 Tablet Dispense The Accompanying Medication Guide To Each Patient. Abbvie Genentech (Venetoclax Spl 09)

Ndc 0074-0566-11 Rx Only Venclexta® (venetoclax Tablets) 50 mg Per Tablet1 Tablet Dispense The Accompanying Medication Guide To Each Patient. Abbvie Genentech (Venetoclax Spl 09)
Packaging label for Venclexta 100 mg film-coated tablets, containing venetoclax. The label shows that the carton contains 120 tablets, with directions to store the product at or below 86°F (30°C) and to keep out of reach of children. The labeler is AbbVie Inc., and the product is manufactured and marketed by AbbVie Inc. and Genentech USA, Inc. The label also includes barcodes and a placeholder for a 2D barcode with expiration and lot number details.*
FDA Label Image

Ndc 0074-0576-22 Rx Only Venclexta® (venetoclax Tablets) 100 mg Attention: Dispense And Store Venclexta In Original Container To Protect From Moisture.120 Tablets Dispense The Accompanying Medication Guide To Each Patient. Abbvie Genetech (Venetoclax Spl 0a)

Ndc 0074-0576-22 Rx Only Venclexta® (venetoclax Tablets) 100 mg Attention: Dispense And Store Venclexta In Original Container To Protect From Moisture.120 Tablets Dispense The Accompanying Medication Guide To Each Patient. Abbvie Genetech (Venetoclax Spl 0a)
Venclexta 100 mg film-coated tablet carton label by AbbVie Inc., also marketed by Genentech USA. The label states one tablet per blister, oral route, provides storage instructions, and includes barcodes, NDC (0074-0576-11), and standard prescription drug warnings. The design features blue and white colors with the Venclexta logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.